on the allergen type and extracts, the type of immunotherapy (standard vs. cluster vs. rush) and induction versus maintenance phase [3, 4] . Retrospectively, they range from 0.01 to 0.37% [5, 6] , prospectively, around 0.1% [7] of injections. The rate of SR per patient varies from 1.1 to 7.4 [5, 8] , and most are grade I and II reactions.
. Treatment included inhaled and intramuscular epinephrine, intravenous clemastine and methylprednisolone, with a beneficial response in all. All cases were reported to the pharmacovigilance and documented as critical incidence reports.
We retrospectively identified all patients who had received specific immunotherapy with respiratory allergens, the products used and the number of injections given. In 2004, 158 patients with rhinoconjunctivitis and/or asthma received a total of 1,630 allergen doses of NovoHelisen (Allergopharma) ( table 1 ), 559 doses of Alutard SQ (ALK Denmark) and 300 doses of Allergovit (Allergopharma). A total of 20 extracts was administered to 10 patients before the 11 SR. The calculated incidence of SR was 6.3% in the patients, and the respective proportions in the preparations were: in 6 patients, Novo-Helisen 14/1,630 doses (0.0066%), in 3 patients, Alutard SQ 4/559 doses (0.007%), and in 1 patient Allergovit 1/300 doses (0.0033%).
The patients and reactions were evaluated with regard to the following risk factors: (1) extract error (composition, concentration), (2) dosing errors, (3) ignored contraindications (symptoms to allergen exposure, uncontrolled asthma, intercurrent infections, interfering drugs), (4) introduction versus maintenance phase, and (5) accidental intravascular injection.
No errors with regard to extract selection or dosing could be identified. Injections were given subcutaneously on the lateral upper arm after careful aspiration. The 6 patients who had received Novo-Helisen preparations were further analyzed. The administered preparations were sent back to the company and analyzed with regard to allergen content. All solutions contained the respective allergens in correct concentrations. All 10 patients continued SCIT up to a complete 3-year course without further SR.
A logistic regression analysis was performed to assess the statistical significance of the incidence rates between the last 4 weeks of 2004 as compared to the rest of the year. Five of the 11 cases occurred during these last 4 weeks of 2004. The analysis was adjusted for potential heterogeneity of susceptibility between subjects and provided a p value of 0.0002. To test the hypothesis that nonrandom clustering occurs in at least 1 of the 52 possible 4-week periods against the null-hypothesis of side effects occurring independently of each other and without any association with calendar time, this p value would have to be multiplied by 52 (Bonferroni adjustment). Therefore, an adjusted p value of 0.01 might be appropriate. In addition, we conducted a simulation analysis in which we randomly distributed the 11 events across all sessions of the year. As a measure of heterogeneity, we considered the variance of successive distances between events. These distances were defined as the number of sessions between consecutive events augmented by 1. Closing the 'string' of sessions to a 'necklace' enabled the determination of an 11th distance. In less than 10 out of 10,000 randomly generated distributions, the respective variance was higher than the one observed in our data, suggesting that there was even less visible clustering. In summary, the higher incidence of severe allergic reactions observed in the 4th quarter of 2004, and more specifically during the last month of 2004, can be explained as a rare clustering of random events. In table 1 , the overview of the 4 quarters of 2004 with the number of subcutaneous injections of allergen extracts, the number of sessions and the number of the 3 different preparations used is given.
Novo-Helisen was the most frequently administered extract (85.5%) with a rate of 7 adverse SR among 1,630 administered doses (0.0066%). There was no statistical significance with regard to other preparations and no difference between induction and maintenance doses. We further analyzed possible causes of SR to this extract. Neither composition nor dilution or dosing errors nor ignored contraindications could be identified. Since most reactions occurred outside of the pollen season, this factor is most likely not relevant [9] . Having excluded -as far as possible -all known causes for SR [10, 11] and having assured a proper subcutaneous injection technique, we suppose that the question of where the allergen is deposited in the subcutaneous tissue in relation to blood vessels in particular might be of relevance with regard to the speed of systemic distribution of the allergen. However, there are no hard data on this issue. For the cluster of SR in 2004, we suppose that most likely, paravascular injections were responsible for the SR, which began most often within a few minutes after the injection.
According to our estimates, the risk of observing a comparable clustering in a given year just by chance is ! 1% in our setting. In the following year 2005, 4.6% of patients (as compared to 6.32% in 2004) suffered SR during SCIT. Exact rates per injection were not calculated.
In conclusion, we have seen comparable rates of SR in SCIT as reported in the literature [5] . Particular risk factors such as uncontrolled asthma, cluster treatment or allergen extracts from a particular manufacturer [12] [13] [14] were not present. Mix-up of extracts or wrong doses could not be identified. Also, other patient-or physician-related mistakes were not present. Severe allergic reactions occur rarely upon SCIT, and even in a well-controlled, experienced setting, their onset is possible at any time. However, the cluster we observed is a very rare event.
